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  55 
Abstract 56 
Introduction: Recent trials have emphasized the importance of a precise patient selection for 57 
cytoreductive nephrectomy(CN). In 2013, a nomogram was developed for pre- and 58 
postoperative prediction of the probability of death (PoD) after CN in patients with metastatic 59 
renal cell carcinoma (mRCC). To date, the single-institutional nomogram which included 60 
mostly patients from the cytokine era has not been externally validated. Our objective is to 61 
validate the predictive model in contemporary patients in the targeted therapy era. 62 
 63 
Methods: Multi-institutional European and North American data from patients who underwent 64 
CN between 2006 and 2013 were used for external validation.  Variables evaluated included 65 
pre-operative serum albumin and lactate dehydrogenase levels, intraoperative blood 66 
transfusions (yes/no) and postoperative pathologic stage (primary tumour and nodes). In 67 
addition, patient characteristics and MSKCC risk factors were collected. Using the original 68 
calibration indices and quantiles of the distribution of predictions, Kaplan-Meier estimates and 69 
calibration plots of observed versus predicted PoD were calculated. For the preoperative 70 
model a decision curve analysis (DCA) was performed. 71 
 72 
Results:   Of 1108 patients (median OS of 27 months [95% CI 24.6-29.4]), 536 and 469 73 
patients had full data for the validation of the pre-and postoperative models, respectively. The 74 
AUC for the pre- and postoperative model was 0.68 [95% CI 0.62-0.74] and 0.73 [95% CI 75 
0.68-0.78], respectively. In the DCA the preoperative model performs well within threshold 76 
survival probabilities of 20-50%. Most important limitation was the retrospective collection of 77 
this external validation dataset.  78 
 79 
Conclusions: In this external validation, the pre- and postoperative nomograms predicting 80 
PoD following CN were well calibrated. Although performance of the preoperative nomogram 81 
was lower than in the internal validation, it retains the ability to predict early death after CN. 82 
 83 
 84 
  85 
1. Introduction 86 
 87 
Renal cell carcinoma (RCC) accounts for approximately 3% of all adult malignancies 88 
and 90-95% of all kidney neoplasms[1] [2]. Fifteen to 30% of the patients are diagnosed with  89 
metastatic renal cell cancer (mRCC) at presentation[3]. 90 
The current European Association of Urology (EAU) RCC Guidelines recommend 91 
cytoreductive nephrectomy (CN) in patients with primary mRCC with a good performance 92 
status, a large primary tumor and low metastatic volume.[4] In the cytokine era, CN was 93 
supported by two landmark randomized controlled trials (RCTs) [5, 6] A combined analysis of 94 
both studies yielded a median survival of 13.6 months for nephrectomy plus interferon vs. 7.8 95 
months for interferon alone, representing a 31% decrease in the risk of death (p=0.002) and 96 
an absolute OS advantage of 5.8 months [7]. With the advent of targeted therapy(TT) the 97 
utility if CN in patients with mRCC has been clinically challenged although multiple arguments 98 
in favor of CN in this setting remain[8, 9].  Two RCTs to investigate the role and sequence of 99 
CN were recently presented (CARMENA Trial - NCT00930033; EORTC SURTIME 100 
NCT01099423). Results from both trials suggest that only very few indications for CN remain 101 
for patients who require systemic therapy with TT.[10, 11] Nonetheless, as the systemic 102 
therapy landscape moves quickly into second generation of RCC immunotherapy, it is 103 
unlikely that we will define the ideal role of CN in patients treated with these new therapeutic 104 
agents.[12] 105 
Patients with mRCC are clinically and pathologically heterogeneous. The results of 106 
CARMENA confirm that they present a great variability in oncologic outcomes after CN and 107 
systemic therapy.[10] CN has a 3-4% mortality rate and some patients will not derive a clinical 108 
benefit from this potentially morbid surgical resection.[13] Indeed, up to 15% of patients never 109 
receive systemic therapy following CN due to rapid disease progression or perioperative 110 
death. [13]  Validated, accurate and clinically useful models to predict survival are paramount 111 
in the selection of patients in whom CN may still be indicated.[14] Retrospective studies have 112 
identified potential clinical and laboratory risk factors that can be used to identify patients 113 
unlikely to benefit from cytoreductive surgery.[15-17] [18]. Although risk models like the 114 
Memorial Sloan Kettering Cancer Center (MSKCC) or International Metastatic Renal Cell 115 
Carcinoma Database Consortium (IMDC) models are widely used to assess the prognosis of 116 
patients with mRCC, they are not predictive for outcome after CN.[23,24] Therefore, 117 
predictive models, based on preoperative clinical factors are needed to define the role of CN 118 
for the individual patient. 119 
In 2013, a nomogram was developed for the pre- and postoperative prediction of the 120 
probability of death (PoD) after CN.[17] Although this nomogram discriminates between long 121 
and short-term survivors, it was generated from a single-institutional database, included 122 
patients from the cytokine era and has not been externally validated. Whereas non-validated 123 
models have limited utility in clinical practice,[19] we tested the validity of this model in a 124 
contemporary multi-institutional European and North American dataset of patients treated in 125 
the targeted therapy era.  126 
 127 
2. Methods 128 
 129 
2.1 Participants 130 
We included patients who underwent CN for mRCC between 2006 and 2013, from 9 131 
European and North American high-volume cancer centers (Netherlands Cancer Institute, 132 
Amsterdam, Netherlands; Umeå University Hospital, Umeå, Sweden; Medical University of 133 
Vienna, Vienna, Austria; Haukeland University Hospital Bergen, Norway; Addenbrooks 134 
Hospital, Cambridge, UK; Western General Hospital, Edinburgh, UK; Ludwig-Maximilians-135 
University Hospital, Munich, Germany; Uniklinik Cologne, Cologne, Germany; Fox Chase 136 
Cancer Center, Philadelphia) as well as patients in the Canadian Kidney Cancer Information 137 
System (prospective data from 15 academic institutions across Canada). Contributing centers 138 
had appropriate institutional review board approval for data collection. For patients to be 139 
included in the pre-operative model validation cohort full data on pre-operative serum albumin 140 
and lactate dehydrogenase (LDH) and status at follow-up were required. For the 141 
postoperative model validation, full data on pre-operative albumin, pre-operative LDH, pN 142 
stage (N0/x vs. N1 vs. N2), intraoperative blood transfusion (no vs. yes); pT-stage >= pT3 (no 143 
vs. yes) and status at follow-up were required.  144 
 145 
2.2 Source of data 146 
A global database from the individual institutions’ renal cancer databases was 147 
constructed collecting the following variables: age, gender, number of metastatic sites, 148 
presence of metastasis in specific sites (for sites see Table 1), ECOG performance status, 149 
MSKCC risk group, pre-operative albumin, pre-operative LDH,  intraoperative transfusions, 150 
RCC histological subtype, pT-stage,  pN-stage, first line systemic treatment and second line 151 
systemic treatment. 152 
 153 
2.3 Statistical analysis 154 
The primary end-point was overall survival (OS) at 6 months (for the pre-operative 155 
model validation) and at 12 months (for the post-operative model validation). OS was defined 156 
as the time from CN to death or censored at date of last follow-up.  157 
The predictive accuracy of the model was assessed by concordance index, which is 158 
the area under the receiver operating curve (ROC) for time-to-event data. Time-dependent 159 
ROC curves were calculated using the Nearest Neighbor Estimation method[20]. The 95% 160 
confidence interval (CI) was obtained using the bootstrap percentile method with 2000 161 
bootstrap replicates. A concordance index of 0.5 represents no predictive discrimination and 162 
an index of 1 represents perfect ability to distinguish patients. Calibration was assessed by 163 
grouping patients into deciles according to their predicted risk. The Kaplan-Meier estimate in 164 
each decile of the observed probability of death at 6 months was plotted against the mean 165 
predicted risk in a calibration plot and a locally-weighted regression line was added. Software 166 
R version 3.4.4 with package survivalROC version 1.0.3.  167 
To determine the clinical value of the model, decision curve analysis was used.[21] 168 
We defined that only patients who survived for 6 months or more may potentially have 169 
benefited from CN. To find the net benefit of the treatment strategy using the prediction from 170 
the preoperative nomogram, we looked at each combination of predicted and true benefit, 171 
and compared the utility values obtained with this strategy with the utility of the default 172 
strategy (treating all patients). We chose a 20% threshold for risk of death at 6 months after 173 
CN, meaning that patients with lower than 20% risk of death would not benefit from not 174 
recommending CN. Finally, to test the clinical value of the nomogram, we assessed the 175 
calibration (i.e., compared the predicted 6-months PoD of the preoperative nomogram to the 176 
observed 6-months rate of death after CN) in each risk group of the MSKCC prognostic 177 
model. 178 
 179 
 180 
3. Results 181 
Between 2006 and 2013, 1108 patients underwent CN. Median follow-up of the 182 
subjects still alive was 24 months [range 0-123 months]. Median OS was 27 months [95% CI 183 
24.6-29.4]. Of those patients, 536 and 469 patients had complete data for the validation of the 184 
preoperative and postoperative models, respectively . (Figure 1) Patient characteristics are 185 
listed in Table 1 and Supplementary Table 1. The majority of patients received systemic 186 
therapy.  187 
 188 
3.1 Preoperative model  189 
The median OS of the 536 patients included in the external validation of the 190 
preoperative model was 21.0 months [95% CI 17.7-24.3]. The AUC for the preoperative 191 
model was 0.68 [95% CI 0.62-0.74].The calibration plot indicates that the risk model is well 192 
calibrated (Figure 2) Decision curve analysis demonstrate that the model has a greater net 193 
benefit compared with the strategies of using CN in all or none of the patients when examined 194 
within the threshold survival probabilities of 20-50%. (Figure 3) If the threshold was set 20%, 195 
then 458 patients would have been considered low-risk (prediction below 20%) and 80.3% 196 
(95% CI 76.7–84.1) of them would still be alive at 5 years. With the 50% risk threshold, 515 197 
patients would have got a predicted risk below 50% and 78.7% of them would still be aliveat 5 198 
years.  199 
 200 
3.2 Postoperative model 201 
The median OS of the 469 patients included in the external validation of the 202 
postoperative model was 20.6 months [95% CI 17.5 – 23.7]. The AUC for the postoperative 203 
model was 0.73 [95% CI 0.68-0.78]. The calibration plot shows that the model is well 204 
calibrated and underestimates the PoD to a minor extent. (Figure 4) 205 
 206 
3.3 Performance of the preoperative model per MSKCC prognostic risk group 207 
A total of 450 patients had full data available to assign them to MSKCC favorable, 208 
intermediate and poor prognosis. Median OS per MSKCC risk group were as published 209 
previously [22]. When separating patients with full data available into MSKCC risk groups, the 210 
observed 6-months rate of death after CN in patients with intermediate and poor prognosis 211 
was higher than the predicted 6-months probability of death (Supplementary Figure 1).  212 
 213 
4. Discussion  214 
Here we present the largest external validation and comparison of a predictive model 215 
assessing the preoperative PoD for patients being considered for CN. The model was 216 
validated using a contemporary cohort of patients receiving targeted therapy in association 217 
with CN. This is a multi-institutional study receiving contributions from centers across Europe 218 
and North America, representing a true external validation. A previous attempt to validate this 219 
model [22] included only a smaller series with multiple imputations to overcome significant 220 
quantities of missing data. Moreover those authors did not obtain the original model and 221 
calibration indices. 222 
 223 
Our external validation revealed that the accuracy of the preoperative model was 224 
lower (0.68) than the one reported in the MD Anderson internal validation cohort (0.76).[17] 225 
The decision curve analysis demonstrates that there is a certain range of probability 226 
thresholds (pt) within which the prediction model is of value (20-50%). We estimated the 227 
range of pt in a typical CN population, where the typical threshold probability of death at 6 228 
months would allow the patient and their urologists to consider CN, as being 20-40%. Overall, 229 
this demonstrates that the model is of clinical value. On the other hand, if for example it were 230 
the case that clinicians offered CN only if there was less than 15% of PoD at 6 months, the 231 
model would have a lesser role. The accuracy for the post-operative model (0.73) was similar 232 
to the one found in the internal validation (0.74).[17]. However, this model has limited clinical 233 
application when compared with the pre-operative model which estimates the PoD before CN 234 
is performed. 235 
 236 
Adequate patient selection for CN is critical in the management of mRCC. Although 237 
the results of CARMENA demonstrate non-inferiority of sunitinib versus CN followed by 238 
sunitinib[10], it has to be acknowledged that the study did not reach full accrual and included 239 
many poor surgical candidates, suggesting selection bias by physicians responsible for 240 
selecting patients into the trial. In addition, a minority of patients still required secondary CN 241 
when treated with sunitinib only. As a consequence, the results of CARMENA are not 242 
universally accepted and suggestions are made to carefully select potential candidates for CN 243 
instead of abandoning the procedure completely[23]. 244 
Multiple retrospective studies have identified factors associated with worse outcomes 245 
following CN[15]. Negative prognostic factors included systemic symptoms (e.g. weight loss, 246 
fever) at the time of CN, multiple sites of metastatic disease, Fuhrman nuclear grade of 4, 247 
sarcomatoid dedifferentiation, coagulative necrosis in the tumor, abnormally high thyroid-248 
stimulating hormone  (TSH) levels, retroperitoneal lymphadenopathy, or tumor thrombus. 249 
Several prognostic models of OS or progression free survival (PFS) in mRCC were 250 
developed in the cytokine and targeted therapy era [24] and have been externally validated 251 
[25].  One of the most commonly used prognostic models, the MSKCC risk score, has been 252 
established in the cytokine era. Karnofsky PS <80%, high serum lactate dehydrogenase (> 253 
1.5 times upper limit of normal), low haemoglobin (< lower limit of normal), high "corrected" 254 
serum calcium (> 10 mg/dL), and absence of prior nephrectomy were used to categorize 255 
patients as being at favourable, intermediate or poor risk. The absence of prior nephrectomy 256 
was later changed to the factor ‘time from diagnosis to systemic treatment < 1 year’ [26].  257 
Similary, the IMDC model using components of the MSKCC model with the addition of 258 
platelet and neutrophil count but has been validated for use in clinical trials and patient care in 259 
the era of targeted therapy  [27]. A retrospective study involving 1652 patients with or without 260 
CN suggests that patients with an estimated OS of < 12 months and IMDC poor risk of 4 or 261 
more factors derive no benefit from CN [28]. However, despite being used to aid in the 262 
decision to offer CN, the IMDC and MSKCC models are prognostic and not predictive for the 263 
PoD after surgery. In addition, they included both metachronous and primary mRCC in the 264 
validation sets.  265 
Although in our study the observed 6-months death after CN is higher in MSKCC 266 
intermediate and poor risk patients compared to the predicted 6-months PoD with the 267 
nomogram, it should be kept in mind that the MSKCC and IMDC models in addition to not 268 
being predictive merely provide a categorical assessment of prognosis, expressed as median 269 
OS, for all patients within the same risk group. Therefore, the predictive pre-operative model 270 
which can estimate an individual’s PoD at 6 months prior to CN retains clinical value in this 271 
setting. This value is especially apparent for patients of MSKCC intermediate risk, which 272 
generally constitute 60-70% of all mRCC patients. While their median OS is 26 months, the 273 
observed rate of death at 6 months was almost 18%. Although the pre-operative nomogram 274 
underestimates the 6 months death rate, it provides a tool to identify those with a high 275 
probability of a poor outcome in conjunction with CN among patients with intermediate risk. 276 
From the surgeon and patient’s perspective identification of patients unlikely to benefit from 277 
CN prior to surgery is the ultimate goal. The model that was the subject of this external 278 
validation was developed from a previous study by Culp et al who established a risk score 279 
from 566 patients who underwent CN, which included: 1) raised LDH, 2) low albumin, 3) 280 
symptoms at presentation caused by metastatic site, 4) metastasis in the liver, 5) 281 
retroperitoneal or 6) supradiaphragmatic adenopathy and 6) >=cT3 stage. OS of 110 patients 282 
with mRCC who did not undergo CN was used as a reference group.  Patients who 283 
underwent CN had a median OS of 12.2 months, 22.7months and 40.6months for ≥4, 3-1 or 0 284 
risk factors, respectively.[14] Patients who had ≥4 risk factors did not appear to benefit from 285 
CN.  286 
 287 
The accuracy of risk models based on clinical factors is limited, regardless of their 288 
prognostic or predictive use. The AUC obtained in our external validation of the prediction 289 
model of survival after CN compares very favorably with those obtained for prognostic 290 
models. In one of the largest external validations done thus far, the concordance index was 291 
0.71(95% CI 0.68-0.73) for the IDMC model [24], 0.662 (95% CI 0.636–0.687) for the CCF 292 
model [29], 0.640 (0.614–0.665) for the French model[30], 0.668 (0.645–0.692) for  the 293 
IKCWG model[31], and 0.657 (0.632–0.682) for the MSKCC model[26].[25]  294 
 295 
This external validation has a number of limitations. First of all, the main weakness is 296 
the retrospective design, despite being based on prospective renal cancer databases. 297 
Complete data for validation was only present in half of the total cohort and relatively few 298 
patients had complete information on cancer specific survival (CSS) available. Secondly, It is 299 
important to note that we used OS and not CSS as reported in the original model [17]. This 300 
may in part explain the higher observed 6-months death rate compared to the predicted 6-301 
months probability of death since patients who died of surgical complications are included in 302 
OS but would be excluded from CSS. However, in the setting of mRCC the potential 303 
difference between both outcome measures is likely to be small. It could even be argued that 304 
OS is the correct endpoint to evaluate the model, because in deciding whether to perform CN 305 
any death should be considered as a failure, regardless if that death was attributed to cancer. 306 
Thirdly, only data for comparison with the MSKCC model were available, which excludes the 307 
more contemporary IMDC model from the analysis. Despite this limitation, our study 308 
represents the largest cohort validating a predictive model developed to select patients for 309 
CN. 310 
 311 
5. Conclusion  312 
In this external validation, the pre- and postoperative nomograms predicting PoD following 313 
CN were well calibrated. Although performance of the preoperative nomogram was lower 314 
than in the internal validation, it retains the ability to predict early death after CN. 315 
 316   317 
 318  319 
FIGURE AND TABLE LEGEND 320 
 321 
 322 
 323 
Figure 1 – Flowchart of 1108 patients that underwent cytoreductive nephrectomy (CN) 324 
LHD= Lactate dehydrogenase 325 
 326 
Figure 2  Calibration plot – Pre operative model 327 
 328 
Figure 3 Decision curve analysis of the Pre operative model.  329 
The blue line represents treating all patients. The black line represents treating no patients. 330 
The red line represents treating patients  based on their predicted risk of death within 6 331 
months. 332 
 333 
Figure 4 - Calibration plot – Post operative model 334 
 335 
Supplementary Figure 1 - Comparison of the observed versus expected probability of 336 
death at 6 months across MSKCC Risk Groups for the 450 patients with full data for 337 
MSKCC risk assignment available. (95% confidence interval of the observed survival 338 
percentage.) 339  340  341 
Table 1 - Patient characteristics 342 
 343 
Supplementary table 1 Patient characteristics: Included versus excluded patients 344 
 345 
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Figure 1 – Flowchart of 1108 patients that underwent cytoreductive 
nephrectomy (CN)                          LHD= Lactate dehydrogenase  
1108 patients underwent Cytoreductive nephrectomy 
536 patients had full data to validate the preoperative model  469 patients had full data to validate the post-operative model  
Excluded  N=17 (Missing status at follow up) 
1091 patients with  known status at follow up 
Excluded  N= 555 (Albumin or LDH missing) Excluded  N= 622(at least one of the post-op model variables missing) 
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Table 1 – Patient characteristics  
 
Patient characteristics Pre-op model 
Median [IQR] or N(%) 
Post-op model 
Median [IQR] or 
N(%) 
Number of patients 536 469 
Age (yrs) 64 [56-70] 64 [56-70] 
Gender 
Female 
Male 
 
165 (30.8%) 
371 (69.2%) 
 
148(31.6%) 
321(68.4%) 
Albumin (g/dL) 3.9 [3.4-4.3] 3.9[3.4-4.3] 
LDH (IU/L) 202.5[164.3-300] 204[165.0-311.5] 
Primary tumour 
pT1 
pT2 
pT3 
pT4 
 
69(13.1%) 
70(13.3%) 
338(64.4%) 
48(9.1%) 
 
61(13%) 
59(12.6%) 
304(64.8%) 
45(9.6%) 
Number of metastatic sites 
1 
2 
3 
>=4 
 
249(48.3%) 
161(31.3%%) 
78(15.1%) 
26(5.1 %) 
 
227(50.7%) 
143(31.9%) 
61(13.6%) 
16(3.6%) 
Metastatic sites 
-lung only metastasis 
- lung 
-brain metastasis 
-liver metastasis 
-bone metastasis 
-adrenal 
-lymphnodes 
- other sites 
 
124 
245 
56 
87 
194 
79 
204 
118 
 
119 
210 
53 
72 
173 
74 
167 
94 
Table 1 Click here to download Table Table 1 .docx 
Subtypes 
Clear cell  
papillary 
Chromophobe 
RCC other  
 
420(85.7%) 
45(9.2%) 
5(1.0%) 
19 (3.9%) 
 
373(85.9%) 
39(9%) 
3(0.7%) 
18(4.1%) 
MSKCC score 
-Favourable  
-Intermediate  
-Poor 
- Missing 
 
24(5.3%) 
276(61.3%) 
150(33.3%) 
86  
 
24(6.1%) 
233(59.4%) 
135(34.4%) 
77  
ECOG performance status 
0 
1 
2 
3 
4 
 
264 (55.6%) 
124(26.1%) 
81(17.1%) 
5(1.05%) 
1(0.2%) 
 
231(54.2%) 
113(26.5%) 
76(17.8%) 
5 (1.2%) 
1(0.2%) 
1st line Targeted therapy 
- sunitinib 
- pazopanib 
- Sorafenib 
- Everolimus 
- Bevacizumab 
- Temsirolimus 
- Unknown TKI 
- Other 
- No systemic treat 
- Missing 
 
220(58.4%) 
53 (14.1%) 
16(4.2%) 
4(1%) 
3(0.8%) 
2(0.5%) 
3(0.8%) 
11(2.9%) 
65(17.2%) 
159 
 
176(55.3%) 
48(15.1%) 
14(4.4%) 
4(1.3%) 
3(0.9%) 
2(0.6%) 
3(0.9%) 
6(1.9%) 
62(19.5%) 
151 
2nd line therapy 
- sunitinib 
- pazopanib 
- Axitinib 
- Sorafenib 
- Everolimus 
- Bevacizumab 
- Nivolumab 
- Cabozantinib 
- Other 
- No systemic treat 
- Missing 
 
12(7%) 
8(4.7%) 
12(7%) 
18(10.5%) 
21(12.2%) 
1(0.6%) 
2(1.2%) 
1(0.6%) 
3(1.7%) 
94(54.7%) 
364 
 
8(5.7%) 
4(2.8%) 
11(7.8%) 
12(8.5%) 
18(12.8%) 
- 
2(1.4%) 
1(0.7%) 
3(2.1%) 
82(58.2%) 
328 
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